Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Endocrine aspects of bromocriptine therapy in Parkinsonism.

Literature DB >> 104006

Endocrine aspects of bromocriptine therapy in Parkinsonism.

K M Shaw, A J Lees, S Franks, P Daggett, B D Thompson, G M Stern.

Abstract

Plasma growth hormone (GH) concentrations in Parkinsonian patients following 3 months optimum therapy with bromocriptine showed no significant change from pretreatment values, whilst plasma prolactin concentrations were uniformly suppressed. Pretreatment GH and prolactin levels were unrelated to clinical disability, and no correlation between hormonal changes and therapeutic response was found. These results suggest the presence of different dopaminergic receptor mechanisms for GH and prolactin release as well as between the extrapyramidal and neuroendocrine systems.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1978 PMID： 104006 DOI： 10.1007/bf01579074

Source DB: PubMed Journal: J Neural Transm Impact factor: 3.575

26 in total

1. Bromocriptine in Parkinsonism.

Authors: D B Calne; P F Teychenne; L E Claveria; R Eastman; J K Greenacre; A Petrie
Journal: Br Med J Date: 1974-11-23

2. Defective release of growth hormone in parkinsonism improved by levodopa.

Authors: I Mena; G C Cotzias; F C Brown; P S Papavasiliou; S T Miller
Journal: N Engl J Med Date: 1973-02-08 Impact factor: 91.245

3. Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients.

Authors: F Cavagnini; M Peracchi; G Scotti; U Raggi; A E Pontiroli; R Bana
Journal: J Endocrinol Date: 1972-09 Impact factor: 4.286

4. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

Authors: G C Cotzias; P S Papavasiliou; E S Tolosa; J S Mendez; M Bell-Midura
Journal: N Engl J Med Date: 1976-03-11 Impact factor: 91.245

5. Dopamine is an important neurotransmitter in the autonomic nervous system.

Authors: M O Thorner
Journal: Lancet Date: 1975-03-22 Impact factor: 79.321

6. Hypothalamic releasing factors and Parkinson disease.

Authors: T N Chase; A C Woods; M A Lipton; C E Morris
Journal: Arch Neurol Date: 1974-07

7. Letter: Growth-hormone responses in Parkinson's disease.

Authors: J D Parkes; A G Debono; C D Marsden
Journal: Lancet Date: 1976-02-28 Impact factor: 79.321

8. Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone.

Authors: N P Plotnikoff; A J Prange; G R Breese; M S Anderson; I C Wilson
Journal: Science Date: 1972-10-27 Impact factor: 47.728

9. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine.

Authors: F Camanni; F Massara; L Belforte; G M Molinatti
Journal: J Clin Endocrinol Metab Date: 1975-03 Impact factor: 5.958

10. Bromocriptine in parkinsonism. A long-term study.

Authors: A J Lees; S Haddad; K M Shaw; L J Kohout; G M Stern
Journal: Arch Neurol Date: 1978-08

4 in total

1. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.

Authors: H P Vogel; R Ketsche
Journal: J Neurol Date: 1986-06 Impact factor: 4.849